Relmada Therapeutics (RLMD) Cash from Financing Activities (2012 - 2026)
Relmada Therapeutics (RLMD) posted quarterly Cash from Financing Activities of $156.6 million for Q1 2026, up 67.21% quarter-over-quarter from $93.6 million in Q4 2025.
Powered by 
Analysis
Relmada Therapeutics (RLMD) Cash from Financing Activities (2012 - 2026) Analysis & Trends
Relmada Therapeutics (RLMD) has reported Cash from Financing Activities for 13 consecutive years, with $156.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities changed N/A year-over-year to $156.6 million; the TTM figure through Mar 2026 stood at $250.0 million (changed N/A YoY), while the FY2025 annual figure was $93.6 million, up 232034.78% from the prior year.
- Cash from Financing Activities climbed to $156.6 million in Q1 2026 per RLMD's latest filing, from $93.6 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $156.6 million in Q1 2026 and bottomed at -$172487.0 in Q4 2024.
- Historically, Cash from Financing Activities has averaged $32.8 million across 4 years, with a median of $569092.0 in 2022.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities plunged 99.75% — and 2025, when it surged 54386.89%.
- Relmada Therapeutics' Cash from Financing Activities stood at $409883.0 in 2022, then tumbled by 142.08% to -$172487.0 in 2024, then soared by 54386.89% to $93.6 million in 2025, then surged by 67.21% to $156.6 million in 2026.
- Business Quant data shows RLMD's Cash from Financing Activities at $156.6 million in Q1 2026, $93.6 million in Q4 2025, and -$172487.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Relmada Therapeutics | 498.39 Mn | 498.39 Mn | - | -6.42 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -6.42 Mn |
| Mar 31, 2026 | 156.57 Mn |
| Dec 31, 2025 | 93.64 Mn |
| Dec 31, 2024 | -172,487.00 |
| Sep 30, 2024 | -89,601.00 |
| Mar 31, 2024 | 221,747.00 |
| Dec 31, 2022 | 409,883.00 |
| Sep 30, 2022 | 569,092.00 |
| Jun 30, 2022 | 14.09 Mn |
| Mar 31, 2022 | 29.95 Mn |
| Dec 31, 2021 | 161.84 Mn |
| Sep 30, 2021 | 185,156.00 |
| Jun 30, 2021 | 23.99 Mn |
| Mar 31, 2021 | 1.93 Mn |
| Dec 31, 2020 | 944,153.00 |
| Sep 30, 2020 | 1.63 Mn |
| Jun 30, 2020 | 22.89 Mn |
| Mar 31, 2020 | 3.00 Mn |
| Dec 31, 2019 | 113.64 Mn |
| Sep 30, 2019 | 13.64 Mn |